Expression Changes of CX3CL1 and Interleukin-6 Genes During Remission Induction Therapy in Patients with Acute Myeloid Leukemia

  • Mahdiyar Iravani Saadi 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran http://orcid.org/0000-0002-0104-4684
  • Mani Ramzi 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Aliasghar Karimi 2. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran 3. Department of Medical Genetics, Fasa University of Medical Sciences, Fasa, Iran
  • Maryam Owjfard 4. Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mahmoud Torkamani 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Nadiya Kheradmand 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Ahmad Niknam 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Zahed Karimi 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mohammad Kazem Vakil 2. Non Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
  • Mohammad Hosein Yazdanpanah 2. Non Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
DOI: https://doi.org/10.31661/gmj.v10i0.2288
Keywords: CX3CL-1, IL-6, Remission Therapy, Acute Myeloid Leukemia

Abstract

Background: Acute myeloid leukemia (AML) syndrome is a hematologic malignancy due to the extensive clonal proliferation of leukemic precursor cells and is rapidly fatal unless treated or in response to chemotherapy. Cytogenetic findings have an important role in the prognosis and categorization of AML. This study aimed to investigate the expression changes in CX3CL1 and Interleukin-6 (IL-6) genes before and after chemotherapy as remission induction therapy in AML patients. Materials and Methods: In this study, 69 patients (36 males, 33 female) with AML were selected from tertiary medical health centers. A quantitative polymerase chain reaction was performed for mRNA expression of CX3CL1 and IL-6 genes before and after induction chemotherapy using the 2-ΔΔCT method. Results: The expression of CX3CL1 and IL-6 were significantly increased after induction chemotherapy. Also, the ΔCt mean of CX3CL1 and IL-6 mRNA was not significant between AML subtype groups. Conclusion: We showed that chemotherapy significantly increases the expression of CX3CL1 and IL-6, which can be used as a prognostic factor of AML. [GMJ.2021;10:e2288]

References

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.

https://doi.org/10.1182/blood-2009-07-235358

PMid:19880497

Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Investig. 2003;21(6):873-86.

https://doi.org/10.1081/CNV-120025091

PMid:14735692

Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol.2006; 43(2): 89-95.

https://doi.org/10.1053/j.seminhematol.2006.01.002

PMid:16616042

Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol. 2003;21(9):1874-81.

https://doi.org/10.1200/JCO.2003.09.113

PMid:12721266

Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-95.

https://doi.org/10.1182/blood-2007-10-117671

PMid:18390837

Ibrahem L, Mahfouz R, Elhelw L, Abdsalam EM, Soliman R. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia. Blood Cells Mol Dis. 2015;54(1):84-9.

https://doi.org/10.1016/j.bcmd.2014.07.015

PMid:25172541

Li K, Lv XX, Hua F, Lin H, Sun W, Cao WB et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll‐like receptor 2‐mediated cell‐penetrating peptide. Int J Cancer Res. 2014;134(3):692-702.

https://doi.org/10.1002/ijc.28382

PMid:23852533

Nasrollahi SA, Taghibiglou C, Azizi E, Farboud ES. Cell‐penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des. 2012;80(5):639-46.

https://doi.org/10.1111/cbdd.12008

PMid:22846609

Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. NEJM. 2006;354(6):610-21.

https://doi.org/10.1056/NEJMra052723

PMid:16467548

Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci. 2004;20(5):1150-60.

https://doi.org/10.1111/j.1460-9568.2004.03593.x

PMid:15341587

Corcione A, Ferretti E, Pistoia V. CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J Leukoc Biol. 2012;92(1):51-8.

https://doi.org/10.1189/jlb.0112035

PMid:22457367

D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther. Targets. 2010;14(2):207-19.

https://doi.org/10.1517/14728220903540265

PMid:20055718

Sugiyama H, Inoue K, Ogawa H, Yamagami T, Soma T, Miyake S et al. The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma. 1996;21(1-2):49-52.

https://doi.org/10.3109/10428199609067579

PMid:8907269

Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen‐activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999;30(5):1128-33.

https://doi.org/10.1002/hep.510300522

PMid:10534331

Published
2021-12-31
How to Cite
Iravani Saadi, M., Ramzi, M., Karimi, A., Owjfard, M., Torkamani, M., Kheradmand, N., Niknam, A., Karimi, Z., Vakil, M. K., & Yazdanpanah, M. H. (2021). Expression Changes of CX3CL1 and Interleukin-6 Genes During Remission Induction Therapy in Patients with Acute Myeloid Leukemia. Galen Medical Journal, 10, e2288. https://doi.org/10.31661/gmj.v10i0.2288
Issue
Vol. 10 (2021): 2021
Section
Original Article

Copyright (c) 2021 Galen Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).